Resveratrol inhibits the malignant progression of hepatocellular carcinoma via MARCH1-induced regulation of PTEN/AKT signaling

Dai, Hanhan; Li, Minjing; Yang, Wei; Sun, Xiujiang; Wang, Peiyuan; Wang, Xia; Su, Jiaqi; Wang, Xu; Hu, Xuemei; Zhao, Mengnan

doi:10.18632/aging.103338

Cited by 31 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, MK2206 (an AKT inhibitor) and bisperoxovanadium (BPV; a PTEN inhibitor) combined with resveratrol decreased MARCH1 expression more than the singletreatment HCC group. These results suggested that resveratrol affects the biological characteristics of HCC via downregulation of MARCH1 expression (Dai et al, 2020).…”

Section: Resveratrolmentioning

confidence: 82%

Role of antioxidants in the treatment of hepatocellular carcinoma: Integrative review

Locatelli

Jardim

Zancanaro

2021

RSD

View full text Add to dashboard Cite

Theorical framework: Hepatocellular carcinoma is a unique cancer that typically arises in the setting of chronic liver disease at a rate dependent upon the complex interplay between the host, disease, and environmental factors. Unfortunately, with contemporary management, patients with advanced hepatocellular carcinoma have few treatment options, and the prognosis is poor. Objective: Evaluate the role of antioxidants in the treatment of hepatocellular carcinoma. Methodology: It is an integrative review, with a qualitative approach. Based on research on ScienceDirect and PubMed databases, 12 articles were selected that were consistent with the theme and the inclusion and exclusion criteria, through the association of descriptors and keywords. Results: Studies in vivo demonstrated a positive correlation of antioxidants in the treatment of hepatocellular carcinoma. The antioxidants were able to promote inhibition of development tumor through promotes decrease of proinflammatory cytokines IL-1 and IL-6 and changes the ratios of Bax/Bcl2 that supports apoptosis. In oxidative stress, may be able to direct free radical scavenging activity. Among the main antioxidants with advanced preclinical evidence in the treatment of hepatocellular carcinoma is curcumin with tests in humans, and gallic acid, quercetin and resveratrol with several tests in vitro and in vivo. Conclusion: This study highlights that antioxidants can be a promising therapy in the treatment of hepatocellular carcinoma.

show abstract

Section: Resveratrolmentioning

confidence: 82%

Role of antioxidants in the treatment of hepatocellular carcinoma: Integrative review

Locatelli

Jardim

Zancanaro

2021

RSD

View full text Add to dashboard Cite

show abstract

“…Interestingly, SIN down-regulated the MARCH1 protein expression but increased MARCH1 transcription in HepG2 cells. MG132, as a proteasome inhibitor Dai et al (2020) , rescues MARCH1 protein expression in HepG2 cells after SIN treatment. Therefore, SIN-induced MARCH1 down-regulation through proteasomal degradation.…”

Section: Discussionmentioning

confidence: 98%

“…Our Lab found that MARCH1 was over-expressed in HCC cells and tissues, and promoted the proliferation of HCC cells. MARCH1 downregulation induced by siRNA or drugs could inhibit the progression of HCC by down-regulating PI3K-AKT-β-catenin and PTEN/AKT signaling pathways ( Xie et al, 2019a ; Xie et al, 2019b ; Dai et al, 2020 ). However, the molecular mechanism of SIN in inhibiting MARCH1 expression and its downstream signaling molecules is unclear.…”

Section: Introductionmentioning

confidence: 99%

Sinomenine Suppresses Development of Hepatocellular Carcinoma Cells via Inhibiting MARCH1 and AMPK/STAT3 Signaling Pathway

Yang

Feng

et al. 2021

Front. Mol. Biosci.

Self Cite

View full text Add to dashboard Cite

Promotion of apoptosis and suppression of proliferation in tumor cells are popular strategies for developing anticancer drugs. Sinomenine (SIN), a plant-derived alkaloid, displays antitumor activity. However, the mechanism of action of SIN against hepatocellular carcinoma (HCC) is unclear. Herein, several molecular technologies, such as Western Blotting, qRT-PCR, flow cytometry, and gene knockdown were applied to explore the role and mechanism of action of SIN in the treatment of HCC. It was found that SIN arrests HCC cell cycle at G0/G1 phase, induces apoptosis, and suppresses proliferation of HCC cells via down-regulating the expression of membrane-associated RING-CH finger protein 1 (MARCH1). Moreover, SIN induces cell death and growth inhibition through AMPK/STAT3 signaling pathway. MARCH1 expression was silenced by siRNA to explore its involvement in the regulation of AMPK/STAT3 signaling pathway. Silencing MARCH1 caused down-regulation of phosphorylation of AMPK, STAT3 and decreased cell viability and function. Our results suggested that SIN inhibits proliferation and promotes apoptosis of HCC cells by MARCH1-mediated AMPK/STAT3 signaling pathway. This study provides new support for SIN as a clinical anticancer drug and illustrates that targeting MARCH1 could be a novel treatment strategy in developing anticancer therapeutics.

show abstract

“…In vivo experiments have also suggested that MARCH1 may be a potential oncogene in liver cancer [11]. Other studies have found that resveratrol affected the biological characteristics of liver cancer by downregulating the expression level of MARCH1 [13]. In contrast, MARCH1 exerted a tumor suppressor effect in bladder cancer, and ciRs-6 increased the expression level of MARCH1 by sponge adsorption of miR-653 to inhibit the growth of bladder cancer [12].…”

Section: Discussionmentioning

confidence: 99%

MARCH1 Interacts with β-Catenin as a New Oncogene for Gastric Cancer

Wang

Yang

Yan

et al. 2021

Preprint

View full text Add to dashboard Cite

Background:Membrane-associated RING-CH 1 (MARCH1) is an E3 ubiquitin ligase that plays an important role in antigen presentation. The latest research found that MARCH1 can either promote or suppress cancer progression in ovarian, liver, and bladder cancers, but its function in gastric cancer has not been addressed. This study aimed to investigate the role of MARCH1 in gastric cancer.Methods:The Cancer Genome Atlas (TCGA) database was used to evaluate the expression level and biological function of MARCH1 in gastric cancer. We down-regulated and up-regulated the expression level of MARCH1 in gastric cancer cell line AGS by transfecting siRNAs and overexpression plasmids. Then we detected cell proliferation, migration, invasion and apoptosis using CCK-8 assay, transwell chamber assay and flow cytometry respectively. The relationship between MARCH1 and β-catenin was analyzed using western blotting assay. Results:The results showed that the expression of MARCH1 in gastric cancer was elevated and significantly related to clinical stage, tumor grade, and lymph node metastasis. It is worth noting that there was no significant correlation between the increase in MARCH1 expression level and overall survival. In addition, knocking down and upregulating the expression level of MARCH1 significantly affected the proliferation, migration, invasion, and apoptosis of gastric cancer cells. Furthermore, the study found that MARCH1 and β-catenin positively regulated each other, suggesting that MARCH1 may participate in the malignant biological behavior of tumors through the Wnt/β-catenin pathway.Conclusions:In summary, this study shows the function of MARCH1 in the progression of gastric cancer and provides unique insights into the regulatory mechanism of MARCH1 and β-catenin, which indicates that MARCH1 may be a new target molecule for gastric cancer.

show abstract

Resveratrol inhibits the malignant progression of hepatocellular carcinoma via MARCH1-induced regulation of PTEN/AKT signaling

Cited by 31 publications

References 34 publications

Role of antioxidants in the treatment of hepatocellular carcinoma: Integrative review

Role of antioxidants in the treatment of hepatocellular carcinoma: Integrative review

Sinomenine Suppresses Development of Hepatocellular Carcinoma Cells via Inhibiting MARCH1 and AMPK/STAT3 Signaling Pathway

MARCH1 Interacts with β-Catenin as a New Oncogene for Gastric Cancer

Contact Info

Product

Resources

About